DAVID F JARRARD, MD
Urology at Highland Ave, Madison, WI

License number

Wisconsin 37810

Professional information

Dr. David F Jarrard, Madison WI - MD (Doctor of Medicine)

Specialties:

Urology

Address:

1675 Highland Ave, Madison 53792
(608) 263-6420 (Phone)
University Of Wisconsin Urology
600 Highland Ave, Madison 53792
(608) 263-4757 (Phone)
University W Health Urology Clinic
600 Highland Ave, Madison 53792
(608) 263-4757 (Phone)

Certifications:

Urology, 2008

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

1675 Highland Ave, Madison 53792
University Of Wisconsin Urology
600 Highland Ave, Madison 53792
University W Health Urology Clinic
600 Highland Ave, Madison 53792
University of Wisconsin Hospitals And Clinics
600 Highland Ave, Madison 53792

Education:

Medical School
Virginia Commonwealth University School Of Medicine
Graduated: 1989
University Of Chicago Hosps

David F Jarrard, Madison WI

Specialties:

Urologist

Address:

600 Highland Ave, Madison, WI 53792

Board certifications:

American Board of Urology Certification in Urology

Prof At Uw Colleges

Position:

prof at UW Colleges

Location:

Madison, Wisconsin Area

Industry:

Higher Education

Work:

UW Colleges - prof

Alpha Methylacyl A Coenzyme Racemase Detection

US Patent:

2007028, Dec 13, 2007

Filed:

Jun 6, 2007

Appl. No.:

11/759098

Inventors:

Wei Huang - Madison WI, US
David Jarrard - Madison WI, US

International Classification:

G01N 33/574

US Classification:

435007230

Abstract:

A method of detecting the presence or absence of alpha methylacyl A coenzyme racemase (AMACR) is provided. In one embodiment of the method, a fluid including a secretion chosen from at least one of a prostate secretion or a secretion from an accessory glad or a cellular component of the fluid is obtained from a subject. The fluid is contacted with a reagent for detecting AMACR under conditions such that the reagent detects AMACR in the semen. The level of AMACR is determined such as by comparing it to a standard curve. The fluid can be semen or a prostate secretion or another fluid. A kit that can be used with the method is also provided.

Dna Methylation Markers For Prostate Cancer Field Defect

US Patent:

2012013, May 31, 2012

Filed:

Nov 3, 2011

Appl. No.:

13/288607

Inventors:

DAVID F. JARRARD - MADISON WI, US
BING YANG - MADISON WI, US

International Classification:

C40B 30/04, C12Q 1/68

US Classification:

506 9, 435 611

Abstract:

A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.